UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 58

Sortiert nach

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

Pharmaceutics, 2017-11, Vol.9 (4), p.53

2017

Volltextzugriff (PDF)

Review and analysis of FDA approved drugs using lipid-based formulations

Drug development and industrial pharmacy, 2017-11, Vol.43 (11), p.1743-1758

2017

Volltextzugriff (PDF)

Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery

Pharmaceutics, 2021-10, Vol.13 (10), p.1686

2021

Volltextzugriff (PDF)

The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

Pharmaceutics, 2019-02, Vol.11 (3), p.99

2019

Volltextzugriff (PDF)

Solid Lipid Nanoparticles for Pulmonary Delivery of Biopharmaceuticals: A Review of Opportunities, Challenges, and Delivery Applications

Molecular pharmaceutics, 2024-07, Vol.21 (7), p.3084-3102

2024

Volltextzugriff (PDF)

Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs

Antimicrobial agents and chemotherapy, 2020-10, Vol.64 (11)

2020

Volltextzugriff (PDF)

Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration

Antimicrobial agents and chemotherapy, 2020-09, Vol.64 (10)

2020

Volltextzugriff (PDF)

A lipidic delivery system of a triple vaccine adjuvant enhances mucosal immunity following nasal administration in mice

Vaccine, 2019-03, Vol.37 (11), p.1503-1515

2019

Volltextzugriff (PDF)

Development and in vitro characterization of chitosan-coated polymeric nanoparticles for oral delivery and sustained release of the immunosuppressant drug mycophenolate mofetil

Drug development and industrial pharmacy, 2019-01, Vol.45 (1), p.76-87

2019

Volltextzugriff (PDF)

Highly Effective Oral Amphotericin B Formulation against Murine Visceral Leishmaniasis

The Journal of infectious diseases, 2009-08, Vol.200 (3), p.357-360

2009

Volltextzugriff (PDF)

Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections

Pharmaceutics, 2022-10, Vol.14 (11), p.2316

2022

Volltextzugriff (PDF)

Assessing the In Vivo Effectiveness of Cationic Lipid Nanoparticles with a Triple Adjuvant for Intranasal Vaccination against the Respiratory Pathogen Bordetella pertussis

Molecular pharmaceutics, 2022-06, Vol.19 (6), p.1814-1824

2022

Volltextzugriff (PDF)

Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells

Drug development and industrial pharmacy, 2019-01, Vol.45 (1), p.21-26

2019

Volltextzugriff (PDF)

A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model

PLoS neglected tropical diseases, 2010-12, Vol.4 (12), p.e913-e913

2010

Volltextzugriff (PDF)

Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans

International journal of pharmaceutics, 2009-05, Vol.372 (1), p.76-84

2009

Volltextzugriff (PDF)

Lipid-lowering Activity of Natural and Semi-Synthetic Sterols and Stanols

Journal of pharmacy & pharmaceutical sciences, 2015-01, Vol.18 (4), p.344

2015

Volltextzugriff (PDF)

Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model

European journal of pharmaceutical sciences, 2012-08, Vol.46 (5), p.323-328

2012

Volltextzugriff (PDF)

Investigation into spinal anesthetic failure with hyperbaric bupivacaine: the role of cold exposure on bupivacaine degradation

Canadian journal of anesthesia, 2019-07, Vol.66 (7), p.803-812

2019

Volltextzugriff (PDF)

The functional roles of poly(ethylene glycol)‐lipid and lysolipid in the drug retention and release from lysolipid‐containing thermosensitive liposomes in vitro and in vivo

Journal of pharmaceutical sciences, 2010-05, Vol.99 (5), p.2295-2308

2010

Volltextzugriff (PDF)

Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model

Lipids in health and disease, 2011-08, Vol.10 (1), p.135-135, Article 135

2011

Volltextzugriff (PDF)

Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation

Journal of antimicrobial chemotherapy, 2009-07, Vol.64 (1), p.101-108

2009

Volltextzugriff (PDF)

Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis

Bone Reports, 2021-06, Vol.14, p.100753-100753, Article 100753

2021

Volltextzugriff (PDF)

Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis

International journal of pharmaceutics, 2012-10, Vol.436 (1-2), p.318-323

2012

Volltextzugriff (PDF)

Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature

Drug development and industrial pharmacy, 2015-01, Vol.41 (9), p.1425-1430

2015

Volltextzugriff (PDF)

Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains

Pharmaceutics, 2019-11, Vol.11 (11), p.594

2019

Volltextzugriff (PDF)

1 – 25 von 58

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(56)
Mit Volltextzugriff
(54)

Publikationsform

Sprache

Englisch
(58)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(44)
Pharmacology & Pharmacy
(33)
Animals
(22)
Biological And Medical Sciences
(15)
Administration, Oral
(14)
Mice
(13)
Amphotericin B
(12)
Amphotericin B - Administration & Dosage
(12)
Humans
(12)
Medical Sciences
(12)
Pharmacology. Drug Treatments
(11)
Chemistry, Medicinal
(9)
Chemistry, Pharmaceutical
(9)
Lipids
(8)
Liposomes
(8)
Mice, Inbred Balb C
(8)
Pharmacokinetics
(8)
Amphotericin B - Chemistry
(7)
Amphotericin B - Pharmacokinetics
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

An Overview of Chitosan Nanoparticles and Its Application in Non-Parenteral Drug Delivery

Review and analysis of FDA approved drugs using lipid-based formulations

Chitosan Nanoparticles at the Biological Interface: Implications for Drug Delivery

The Development of Oral Amphotericin B to Treat Systemic Fungal and Parasitic Infections: Has the Myth Been Finally Realized?

Solid Lipid Nanoparticles for Pulmonary Delivery of Biopharmaceuticals: A Review of Opportunities, Challenges, and Delivery Applications

Assessing the Safety, Tolerability, Pharmacokinetics, and Biodistribution of Novel Oral Formulations of Amphotericin B following Single- and Multiple-Dose Administration to Beagle Dogs

Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration

A lipidic delivery system of a triple vaccine adjuvant enhances mucosal immunity following nasal administration in mice

Development and in vitro characterization of chitosan-coated polymeric nanoparticles for oral delivery and sustained release of the immunosuppressant drug mycophenolate mofetil

Highly Effective Oral Amphotericin B Formulation against Murine Visceral Leishmaniasis

Review of Novel Oral Amphotericin B Formulations for the Treatment of Parasitic Infections

Assessing the In Vivo Effectiveness of Cationic Lipid Nanoparticles with a Triple Adjuvant for Intranasal Vaccination against the Respiratory Pathogen Bordetella pertussis

Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells

A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model

Development and characterization of oral lipid-based Amphotericin B formulations with enhanced drug solubility, stability and antifungal activity in rats infected with Aspergillus fumigatus or Candida albicans

Lipid-lowering Activity of Natural and Semi-Synthetic Sterols and Stanols

Assessment of novel oral lipid-based formulations of amphotericin B using an in vitro lipolysis model

Investigation into spinal anesthetic failure with hyperbaric bupivacaine: the role of cold exposure on bupivacaine degradation

The functional roles of poly(ethylene glycol)‐lipid and lysolipid in the drug retention and release from lysolipid‐containing thermosensitive liposomes in vitro and in vivo

Tropically stable novel oral lipid formulation of amphotericin B (iCo-010): biodistribution and toxicity in a mouse model

Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation

Evaluation of La(XT), a novel lanthanide compound, in an OVX rat model of osteoporosis

Efficacy and toxicity of a tropically stable lipid-based formulation of amphotericin B (iCo-010) in a rat model of invasive candidiasis

Novel oral amphotericin B formulation (iCo-010) remains highly effective against murine systemic candidiasis following exposure to tropical temperature

Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains

Suchergebnisse filtern